1st Edition

Monographs in Contact Allergy, Volume 4 Systemic Drugs

By Anton C. de Groot Copyright 2022
    1052 Pages 494 B/W Illustrations
    by CRC Press

    This fourth volume in an exciting and detailed series on contact allergens and drug allergy provides monographs of all 507 systemic drugs which have caused delayed-type cutaneous drug hypersensitivity reactions and/or occupational allergic contact dermatitis. The monographs present: Identification section; Occupational allergic contact dermatitis; and Cutaneous adverse drug reactions from systemic drugs caused by type IV (delayed-type) hypersensitivity, as shown by positive patch tests (e.g. maculopapular eruption, acute generalized exanthematous pustulosis [AGEP], symmetrical drug-related intertriginous and flexural exanthema [SDRIFE], fixed drug eruption, drug reaction with eosinophilia and systemic symptoms [DRESS], and photosensitivity). Separate chapters present an overview of the spectrum of allergic cutaneous drug reactions, diagnostic tests, immediate contact reactions (contact urticaria), and systemic drugs that have acquired delayed-type hypersensitivity only by cross-reactivity.

    Key Features:

    • Presents monographs of all known systemic drugs which have caused delayed allergic cutaneous drug reactions and/or occupational allergic contact dermatitis
    • Provides an extensive literature review of relevant topics of allergenic systemic drugs, part of which is hard or impossible to find in database searches
    • Identifies IUPAC names, synonyms, CAS and EC numbers, structural and chemical formulas, Merck Index monographs, and advises on patch testing
    • Presents immediate contact reactions (contact urticaria) from systemics drugs and delayed-type hypersensitivity in drugs caused only by cross-reactivity
    • Covers an extensive amount of information to benefit dermatologists, allergists, and all others interested in drug allergy

    Introduction. The spectrum of cutaneous adverse drug reactions from systemic drugs caused by delayedtype hypersensitivity. Monographs of systemic drugs that have caused cutaneous adverse drug reactions from delayed-type hypersensitivity. Diagnostic tests in suspected cutaneous adverse drug reactions from systemic drugs. Immediate contact reactions (contact urticaria) from systemic drugs. Systemic drugs that have acquired delayed-type hypersensitivity only by cross-reactivity.


    Anton de Groot - 1980-2002 dermatologist in private practice in two hospitals in ‘s-Hertogenbosch, The Netherlands. PhD 1988: Adverse Reactions to Cosmetics. Author of over 500 publications including 70 book chapters and 19 book titles, of which 7 are international (mainly for dermatologists and allergists) and 12 in Dutch for general practitioners, medical students, skin therapists, podiatrists/pedicures and (parents of) patients with atopic dermatitis. Teacher of general dermatology to medical students/junior doctors at the University of Groningen 2007-2021. Former 15-year Chairman of the Dutch Contact Dermatitis Group. Member of the Editorial Board of the journal Dermatitis. Co-founder and former 10-year Editor-in-Chief of the Dutch Journal for Dermatology and Venereology. Received the American Contact Dermatitis Society Honorary Membership status for his ‘vast contributions to contact dermatitis’ in 2019.

    Allergy: Systemic Drugs by Anton de Groot, the fourth volume in the Monographs in Contact Allergy series. This latest monograph is divided into the following sections: (a) an in­troduction highlighting the need for this text and what is in­cluded, (b) a succinct review of adverse drug reactions (ADRs) from delayed-type hypersensitivity to systemic drugs, (c) monographs on each drug associated with these reactions, (d) an overview of diagnostic tests that can be utilized for evalu­ation, (e) a review of systemic drugs that cause contact urti­caria (immediate contact reactions), and (f) information on systemic drugs that lead to delayed-type hypersensitivity by cross-reactivity only.

    Included are 507 systemic drugs that have been reported to cause delayed-type hypersensitivity as shown by positive patch tests. The monograph for individual drugs, although detailed, also serves a quick reference tool that provides practical infor­mation for the clinician evaluating patients with suspected drng­associated reactions. Essential knowledge, such as information about chemical structures, patch test concentrations and vehi­cles, summaries of the reported literature for reactions to each drug, and cross-reactivity between medications, is also included. In addition to delayed-type hypersensitivity reactions, 21 sys­temic drugs that have been associated with contact urticaria are discussed. An additional 38 systemic drugs that have led to delayed-type hypersensitivity by cross-reactivity only are also included.

    This volume is useful for physicians engaging in advanced patch testing and those interested in expanding their knowledge on the topic of reactions to systemic drugs. It serves as a comprehensive reference for diagnosing patients with sus­pected delayed-type hypersensitivity to systemic drugs. Al­though the primary focus is on patch testing, which in general is rarely associated with severe adverse effects, the author de­tails the increased caution needed when utilizing patch testing and other methods to assess for possible drug-associated reactions.
    Another key area detailed in this volume is the rate of positive patch test results to culprit drugs based on factors such as ADR type and drug category. This information, in part, will help determine the degree of confidence when interpreting test findings and counseling patients about potential risks with future drug exposures.

    The monograph is well organized and comprehensive. It is a must have on the shelves of patch testing experts and those with an interest in drug-associated reactions. It contains in­formation on >500 drugs associated with delayed-type hy­persensitivity reactions and contact urticaria, is thoroughly referenced, and similarly to his prior studies provides impor­tant practical information such as details on patch test con­centrations and vehicles for culprit drugs.

    - Ryan Leveckis, University of South Carolina, Columbia, SC, USA

    - Ari M. Goldminz, MD, Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA